Dutch scientists propose algorithm to keep drugs affordable and accessible

Formule video

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

The paper, "Sustainability and affordability of cancer drugs: a novel pricing model", was written by Carin Uyl-de Groot and Bob Löwenberg of Erasmus University Rotterdam (EUR). Prof. Uyl-de Groot is a member of the EHA Task Force on Fair Pricing and Prof. Löwenberg is a former President of EHA.

Uyl-de Groot and Löwenberg's paper points out the need for transparency to determine drug prices. "Such transparency will enable the price of a drug to be based on the actual costs of R&D, manufacturing, sales, fair marketing and a fair profit margin based on the (expected) annual number of patients treated," the paper states.

Watch the video below for more:

Carin Uyl video


At the core of EHA’s advocacy efforts are five priority themes. Reducing the prices of innovative medicines is one of them. Read our position on this issue here.

Nature article | Press release


Last Updated on Friday 18 May 2018.